全文获取类型
收费全文 | 189498篇 |
免费 | 1891篇 |
国内免费 | 95篇 |
专业分类
耳鼻咽喉 | 1210篇 |
儿科学 | 7050篇 |
妇产科学 | 3349篇 |
基础医学 | 18886篇 |
口腔科学 | 1813篇 |
临床医学 | 13598篇 |
内科学 | 34272篇 |
皮肤病学 | 867篇 |
神经病学 | 18257篇 |
特种医学 | 9226篇 |
外科学 | 29959篇 |
综合类 | 2344篇 |
一般理论 | 4篇 |
预防医学 | 18769篇 |
眼科学 | 2842篇 |
药学 | 10576篇 |
中国医学 | 653篇 |
肿瘤学 | 17809篇 |
出版年
2023年 | 107篇 |
2022年 | 247篇 |
2021年 | 479篇 |
2020年 | 291篇 |
2019年 | 396篇 |
2018年 | 22255篇 |
2017年 | 17650篇 |
2016年 | 19845篇 |
2015年 | 1370篇 |
2014年 | 1378篇 |
2013年 | 1464篇 |
2012年 | 8093篇 |
2011年 | 22103篇 |
2010年 | 19444篇 |
2009年 | 12065篇 |
2008年 | 20431篇 |
2007年 | 22615篇 |
2006年 | 1497篇 |
2005年 | 3037篇 |
2004年 | 4193篇 |
2003年 | 5144篇 |
2002年 | 3202篇 |
2001年 | 374篇 |
2000年 | 501篇 |
1999年 | 305篇 |
1998年 | 351篇 |
1997年 | 319篇 |
1996年 | 193篇 |
1995年 | 203篇 |
1994年 | 174篇 |
1993年 | 131篇 |
1992年 | 104篇 |
1991年 | 135篇 |
1990年 | 173篇 |
1989年 | 134篇 |
1988年 | 86篇 |
1987年 | 74篇 |
1986年 | 66篇 |
1985年 | 58篇 |
1984年 | 55篇 |
1983年 | 55篇 |
1982年 | 44篇 |
1980年 | 54篇 |
1974年 | 27篇 |
1969年 | 27篇 |
1938年 | 60篇 |
1937年 | 25篇 |
1934年 | 32篇 |
1932年 | 58篇 |
1930年 | 48篇 |
排序方式: 共有10000条查询结果,搜索用时 171 毫秒
991.
992.
993.
Luigi Quintieri Cristina Geroni Marianna Fantin Rosangela Battaglia Antonio Rosato William Speed Paola Zanovello Maura Floreani 《Clinical cancer research》2005,11(4):1608-1617
PURPOSE: Nemorubicin (3'-deamino-3'-[2'(S)-methoxy-4'-morpholinyl]doxorubicin; MMDX) is an investigational drug currently in phase II/III clinical testing in hepatocellular carcinoma. A bioactivation product of MMDX, 3'-deamino-3',4'-anhydro-[2'(S)-methoxy-3'(R)-oxy-4'-morpholinyl]doxorubicin (PNU-159682), has been recently identified in an incubate of the drug with NADPH-supplemented rat liver microsomes. The aims of this study were to obtain information about MMDX biotransformation to PNU-159682 in humans, and to explore the antitumor activity of PNU-159682. EXPERIMENTAL DESIGN: Human liver microsomes (HLM) and microsomes from genetically engineered cell lines expressing individual human cytochrome P450s (CYP) were used to study MMDX biotransformation. We also examined the cytotoxicity and antitumor activity of PNU-159682 using a panel of in vitro-cultured human tumor cell lines and tumor-bearing mice, respectively. RESULTS: HLMs converted MMDX to a major metabolite, whose retention time in liquid chromatography and ion fragmentation in tandem mass spectrometry were identical to those of synthetic PNU-159682. In a bank of HLMs from 10 donors, rates of PNU-159682 formation correlated significantly with three distinct CYP3A-mediated activities. Troleandomycin and ketoconazole, both inhibitors of CYP3A, markedly reduced PNU-159682 formation by HLMs; the reaction was also concentration-dependently inhibited by a monoclonal antibody to CYP3A4/5. Of the 10 cDNA-expressed CYPs examined, only CYP3A4 formed PNU-159682. In addition, PNU-159682 was remarkably more cytotoxic than MMDX and doxorubicin in vitro, and was effective in the two in vivo tumor models tested, i.e., disseminated murine L1210 leukemia and MX-1 human mammary carcinoma xenografts. CONCLUSIONS: CYP3A4, the major CYP in human liver, converts MMDX to a more cytotoxic metabolite, PNU-159682, which retains antitumor activity in vivo. 相似文献
994.
Riccardo Valdagni Corrado Italia Paolo Montanaro Angelo Lanceni Paola Lattuada Tiziana Magnani Claudio Fiorino Alan Nahum 《Radiotherapy and oncology》2005,75(1):74-82
BACKGROUND AND PURPOSE: The objectives of the current study were to compare genito-urinary (GU) and gastro-intestinal (GI) toxicities as well as biochemical control (bRFS) in prostate cancer, utilizing conventional (2.0 Gy daily) (STD) or hyperfractionated (HFX) conformal irradiation (CRT). HFX (1.2 Gy BID) was chosen as a radiobiological method to try to reduce long term sequelae without compromising local control. PATIENTS AND METHODS: Three-hundred-and-seventy consecutive patients (pts) entered this prospective, non-randomized trial in the period January 1993-January 2003; 209 were treated with STD and 161 with HFX CRT. All were evaluable for acute toxicity analysis, 179 (STD) and 151 pts (HFX) being evaluable for late sequelae and bRFS analyses. Pt characteristics were not statistically different in the two groups. CRT consisted of a 4-field technique for prostate and/or pelvic nodes and a 5-field boost with rectal shielding. Median doses were 74 and 79.2 Gy for STD and HFX patients respectively, the latter dose being isoeffective for tumour control assuming alpha/beta=10 (EQD(2)=73.9 Gy). Median follow-up was 29.4 months (25.2 mos for STD; 37.7 mos for HFX; P<0.01). The two regimens were compared in terms of acute and late GU and GI toxicities and 5-year bRFS by univariate and multivariate analyses. RESULTS: Acute grade> or =2 GU toxicity was higher in the STD group (48.6% versus 37.3% in HFX, P=0.03), while no significant difference was found for acute GI toxicity. Late grade> or =2 GU and GI toxicities were lower in the HFX group (5-year actuarial rate: GU: 10.1% versus 20.3%, P=0.05; GI: 6.0% versus 10.6%, P=0.18). Five-year bRFS were 70% (+/-13.8%, 95% CI) and 82.6% (+/-7.2%) for STD and HFX, respectively (P=0.44); a trend favouring HFX was found in the subgroup of pts who did not receive hormonal therapy (5-year bRFS: 85.9%+/-12.4% versus 63.9%+/-23.8%, P=0.15). Multivariate analysis revealed only risk groups and age statistically related to bRFS but not fractionation regimen. Using the Nahum-Chapman TLCP model and prostate parameter set, which includes hypoxia, the TLCPs are approximately equal for the two regimens, whereas assuming alpha/beta=1.5 and no hypoxia we obtain 73% for the STD group but only 36% for the HFX group. CONCLUSIONS: As expected from radiobiological considerations, HFX reduces GI and GU late toxicities. Concerning early bRFS, our clinical findings suggest that HFX is no less effective than STD when delivering an isoeffective (alpha/beta=10) dose. Despite the relatively short follow-up, this result appears to be inconsistent with a low alpha/beta ratio for prostate cancer. 相似文献
995.
Pierfrancesco Tassone Paola Neri Renate Burger Rocco Savino Masood Shammas Laurence Catley Klaus Podar Dharminder Chauhan Serena Masciari Antonella Gozzini Pierosandro Tagliaferri Salvatore Venuta Nikhil C Munshi Kenneth C Anderson 《Clinical cancer research》2005,11(11):4251-4258
Interleukin-6 (IL-6) protects multiple myeloma cells against apoptosis induced by glucocorticoids. Here, we investigated whether inhibition of the IL-6 signaling pathway by the IL-6 receptor superantagonist Sant7 enhances the in vivo antitumor effects of dexamethasone on the IL-6-dependent multiple myeloma cell line INA-6. For this purpose, we used a novel murine model of human multiple myeloma in which IL-6-dependent INA-6 multiple myeloma cells were directly injected into human bone marrow implants in severe combined immunodeficient (SCID) mice (SCID-hu). The effect of in vivo drug treatments on multiple myeloma cell growth was monitored by serial determinations of serum levels of soluble IL-6 receptor (shuIL-6R), which is released by INA-6 cells and served as a marker of tumor growth. In SCID-hu mice engrafted with INA-6 cells, treatment with either Sant7 or dexamethasone alone did not induce significant reduction in serum shuIL-6R levels. In contrast, the combination of Sant7 with dexamethasone resulted in a synergistic reduction in serum shuIL-6R levels after 6 consecutive days of treatment. Gene expression profiling of INA-6 cells showed down-regulation of proliferation/maintenance and cell cycle control genes, as well as up-regulation of apoptotic genes in multiple myeloma cells triggered by Sant7 and dexamethasone combination. In vitro colony assays showed inhibition of myeloid and erythroid colonies from normal human CD34(+) progenitors in response to dexamethasone, whereas Sant7 neither inhibited colony growth nor potentiated the inhibitory effect of dexamethasone. Taken together, these results indicate that inhibition of IL-6 signaling by Sant7 significantly potentiates the therapeutic action of dexamethasone against multiple myeloma cells, providing the preclinical rationale for clinical trials of Sant7 in combination with dexamethasone to improve patient outcome in multiple myeloma. 相似文献
996.
Serum PDGF-AB in pleural mesothelioma. 总被引:2,自引:0,他引:2
Rosa Filiberti Paola Marroni Monica Neri Andrea Ardizzoni Pier Giacomo Betta Mara A Cafferata Pier Aldo Canessa Riccardo Puntoni Giovanni Paolo Ivaldi Michela Paganuzzi 《Tumour biology》2005,26(5):221-226
Overexpression of platelet-derived growth factor (PDGF) has been observed in lung and pleural tumors. The aim of this study was to evaluate the diagnostic and prognostic role of serum PDGF in pleural mesothelioma (PM). Four groups of subjects were studied: 93 malignant PM patients, 33 primary non small cell lung cancer patients, 51 subjects exposed to asbestos, defined as high-risk controls, and 24 healthy controls. PDGF-AB mean concentration was higher in PM patients (45.8 ng/ml) than in high-risk controls (33.1 ng/ml) and healthy controls (26.8 ng/ml). Using the cut-off level of 49.8 ng/ml, corresponding to the mean+2SD of PDGF-AB in healthy controls, 43% of PM patients showed positive PDGF-AB levels. Survival was evaluated in 82 PM patients. At the end of the follow-up (median 9.8 months) 80.5% of patients had died. Median survival was 13.1 and 7.9 months for patients with PDGF-AB lower and higher than the cut-off, respectively. Adjusting for age, sex, histology and platelet count, positive PDGF-AB levels were associated with lower survival (OR=1.2, 95%CI: 0.9-1.6), even if not significantly so. In conclusion, serum PDGF may represent a useful additional parameter to prognostic factors already available for PM. 相似文献
997.
Brittany C. Thomas Stephen N. Thibodeau Noralane M. Lindor 《Current colorectal cancer reports》2005,1(2):103-109
Referrals to genetics services are becoming increasingly common for patients who are diagnosed with early-onset colorectal
cancer (CRC) or patients who have a family history of CRC. Microsatellite instability (MSI) testing and immunohistochemical
analysis (IHC) of the patient’s tumor tissue, which assess indirectly the cellular status of DNA mismatch repair, have proven
important tools for geneticists and genetic counselors to determine whether or not these individuals may be at risk for an
inherited cancer syndrome, Lynch syndrome (a subset of hereditary nonpolyposis colorectal cancer). The application of tumor
MSI/ IHC also extends to the group of providers involved in the diagnosis and management of CRC, demonstrating the growing
clinical applicability of MSI/IHC testing. This review discusses the clinical utility of MSI/IHC analysis, including its benefits
and limitations, and addresses some of the current debates surrounding testing. 相似文献
998.
The vast majority of new cases of colorectal cancer, the second most common cause of death in men and women in the United
States, are attributable to environmental rather than genetic causes. Recent research has clarified inconsistencies in the
literature and has explored new pathways through which risk factors may act. This review discusses newly published, selected
interesting and important findings in colorectal cancer etiology; these include postmenopausal hormone use, nonsteroidal anti-inflammatory
drug use, obesity, physical activity, diet, and other confirmed epidemiologic associations. This research provides insight
into mechanisms and offers opportunities for prevention. 相似文献
999.
IGF-I, IGFBP-3 and breast cancer in young women: a pooled re-analysis of three prospective studies. 总被引:2,自引:0,他引:2
Sabina Rinaldi Paolo Toniolo Paola Muti Eva Lundin Anne Zeleniuch-Jacquotte Alan Arslan Andrea Micheli Per Lenner Laure Dossus Vittorio Krogh Roy E Shore Karen L Koenig Elio Riboli P?r Stattin Franco Berrino G?ran Hallmans Annekatrin Lukanova Rudolf Kaaks 《European journal of cancer prevention》2005,14(6):493-496
Prospective cohort studies on breast cancer risk among premenopausal women and insulin-like growth factor I (IGF-I) concentrations have so far included only few cases, and have shown inconsistent relative risk estimates. We pooled 220 cases of breast cancer diagnosed before age 50, and 434 control subjects, from three prospective studies in New York (USA), Ume? (Northern Sweden) and Milan (Italy), and we measured IGF-I and insulin-like growth factor binding protein 3 (IGFBP-3) with common enzyme-linked immunosorbent assays. Overall, IGF-I and IGFBP-3 measurements obtained by the common method showed a positive but not significant relationship with breast cancer risk (odds ratios (ORs) 0.90 [95% confidence intervals (95% CI) 0.50-1.62], 1.63 [0.89-2.97], 1.46 [0.78-2.73] and 1.41 [0.75-2.63] for quintiles of IGF-I, and ORs 0.98 [0.54-1.75], 1.06 [0.59-1.91], 1.04 [0.58-1.87] and 1.77 [0.97-3.24] for quintiles of IGFBP-3). Our results give only moderate support for an association of blood IGF-I with breast cancer risk in young women. 相似文献
1000.